NASDAQ:AKCA - Akcea Therapeutics Stock Price, Forecast & News

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Akcea Therapeutics Inc (NASDAQ:AKCA) announced its earnings results on Tuesday, November, 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.21. The firm had revenue of $20.62 million for the quarter, compared to analyst estimates of $22.54 million. Akcea Therapeutics had a negative return on equity of 33.00% and a negative net margin of 50.71%. The business's revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.73) EPS. View Akcea Therapeutics' Earnings History.

Akcea Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Akcea Therapeutics.

4 brokerages have issued 1 year price targets for Akcea Therapeutics' shares. Their forecasts range from $24.00 to $45.00. On average, they anticipate Akcea Therapeutics' share price to reach $36.00 in the next twelve months. This suggests a possible upside of 104.4% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.

Headlines about AKCA stock have been trending somewhat positive this week, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akcea Therapeutics earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Akcea Therapeutics.

Some companies that are related to Akcea Therapeutics include ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Allakos (ALLK), The Medicines (MDCO), Dr.Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), FibroGen (FGEN), United Therapeutics (UTHR), Global Blood Therapeutics (GBT) and Intercept Pharmaceuticals (ICPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Achaogen (AKAO), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), Apollo Global Management (APO) and Ciena (CIEN).

(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

Akcea Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (0.66%), Alps Advisors Inc. (0.20%), Russell Investments Group Ltd. (0.07%), Squarepoint Ops LLC (0.02%) and Barclays PLC (0.02%). Company insiders that own Akcea Therapeutics stock include Ionis Pharmaceuticals Inc, Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Institutional Ownership Trends for Akcea Therapeutics.

AKCA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC and Alps Advisors Inc.. Company insiders that have sold Akcea Therapeutics company stock in the last year include Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Insider Buying and Selling for Akcea Therapeutics.

AKCA stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Barclays PLC. View Insider Buying and Selling for Akcea Therapeutics.

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKCA stock can currently be purchased for approximately $17.61.

Akcea Therapeutics has a market capitalization of $1.65 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.View Additional Information About Akcea Therapeutics.

The official website for Akcea Therapeutics is http://www.akceatx.com/.

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]